Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 inhibitor plus ctDNA-guided targeted therapy for advanced unresectable hepatocellular carcinoma
ChiCTR1900021896Phase 4Recruiting
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Dec 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nivolumab, pembrolizumab, sorafenib, lenvatinib, Rivoceranib and 3 more in hepatocellular carcinoma (HCC), sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Primary endpoints: Objective response rate, Duration of response and 2 more. Started Dec 2018; status: recruiting.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR1900021896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021896.